Emergent BioSolutions to Release Second Quarter 2020 Financial Results and Conduct Conference Call on July 30, 2020
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 30, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2020, recent...
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense Funding
The Mount Sinai Health System, Emergent BioSolutions (NYSE: EBS), and ImmunoTek Bio Centers today announced that they will collaborate to develop, manufacture, and conduct clinical trials to evaluate...
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &...
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
Emergent BioSolutions (NYSE: EBS) today announced that it will further strengthen its contract development and manufacturing (CDMO) capabilities by expanding into viral vector and gene therapy. The...
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for AstraZeneca’s COVID-19 Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced it will deploy its molecule-to-market contract development and manufacturing (CDMO) services to support the manufacturing of AstraZeneca’s...
Emergent BioSolutions to Participate in Virtual Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences this...
Emergent BioSolutions Statement on U.S. District Court Decision
Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of...
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), part of...
Emergent BioSolutions to Participate in Virtual Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following virtual investor conferences this...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 21, 2020 at 9:00am EDT
Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2020 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 21, 2020 at 9:00 AM...
Emergent BioSolutions Reports Financial Results for First Quarter 2020
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31, 2020. "Emergent is uniquely positioned to respond to the unprecedented challenges of the...
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby Emergent will deploy its contract development and manufacturing (CDMO) services to support the manufacturing of Johnson &...